- Home
- Browse
- National Institutes of Health
- RFA-TR-25-002
Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
- Deadline
- 2027-06-02
- 272 days left
- Award ceiling
- —
- Awards
- —
- Posted
- 2024-12-06
Summary
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. […]
The rest of this announcement — free with an account
- →The full announcement text, not the first two sentences
- →All 3 review criteria reviewers score this against, extracted from this announcement
- →Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- →What similar funded projects received, from 219,000 past awards
No card required. Browsing and your first match are free.
More from National Institutes of Health
See all →NIH Director’s Transformative Research Award for Individual and Group Science (R01 Clinical Trial Optional)
The NIH Director's Transformative Research Award supports collaborative investigative teams or individual scientists who propose unusually bold and innovative research projects, which, if successful, would have a major impact in a broad area of relevance to the NIH.
3 review criteria on fileNIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileNIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileNIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
S. technology development and commercialization.
6 review criteria on fileAlso in rare-disease
Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)
The National Library of Medicine (NLM) wishes to advance groundbreaking and innovative research in bioinformatics, translational bioinformatics and computational biology, which are related areas of biomedical informatics that aim to understand biological data using storage, analytic and interpretive methods.
3 review criteria on fileScreening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)
Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural congenital anomalies (SCAs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs).
3 review criteria on fileCausal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)
6 years.25 billion fewer life years for the United States population.
3 review criteria on fileOfficial announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.htmlSource: nih_guide+grants_gov. Always confirm dates with the funder.